Analystreport

CRISPR Therapeutics AG (NASDAQ: CRSP) had its price target raised by analysts at Piper Sandler from $107.00 to $180.00. They now have an "overweight" rating on the

CRISPR Therapeutics AG - Common Shares  (CRSP) 
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm Check Earnings Report
US:NASDAQ Investor Relations: nasdaq.com/symbol/crsp/real-time